Dual human epidermal growth factor receptor 2 blockade for the treatment of HER2-positive breast cancer

作者：Alvarez Ricardo H^*; Hortobagyi Gabriel N

来源：Breast Cancer, 2013, 20(2): 103-110.

DOI：10.1007/s12282-013-0446-6

• Dual targeted therapy for breast cancer
• Trastuzumab
• Pertuzumab
• Lapatinib
• Everolimus
• Metastatic breast cancer

The introduction of trastuzumab into clinical practice changed the natural course of HER2-positive breast cancer. Currently, treatment with trastuzumab represents the standard of care for HER2-positive breast cancer and this treatment has been approved in the adjuvant, neoadjuvant, and metastatic settings. Besides trastuzumab, two other anti-HER2 agents-lapatinib and pertuzumab-have been approved for the treatment of HER2-positive advanced breast cancer. Strong biologic data support the concept of dual HER2 blockade, with different anti-HER2 agents demonstrating complementary mechanisms of action. Several neoadjuvant and metastatic studies performed in HER2-positive breast cancer using dual HER2 blockade have been proven to outperform anti-HER2 monotherapies. These dual combinations of agents represent a promising therapeutic strategy that is now reaching clinical practice. In this review we describe the results of studies utilizing dual blockade in patients with HER2-positive breast cancer.

• 出版日期2013-4